McDermott Will & Emery advised Osivax on the deal. Osivax, a biopharmaceutical company developing broad-spectrum vaccines against highly mutated infectious viruses, signed an exclusive license option...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised eureKARE on the deal. eureKARE, investment company focused on financing and developing synthetic biology innovation across Europe, announced the creation...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery and Bredin Prat advised Five Arrows Principal Investments on the deal. Goodwin advised Latour Capital, Barings and Arcmont Asset Management. Latour Capital...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised Owkin on the deal. French American startup Owkin, which develops artificial intelligence solutions for medical research, entered into a multi-year...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Diabeloop on the deal. Chammas & Marcheteau advised LBO France. Diabeloop, a Grenoble-based artificial intelligence company specialising in the treatment of...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery has advised the Nov Santé Actions Non Cotées fund on the deal. Nov Santé Actions Non Cotées fund, managed by Eurazeo and dedicated...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery and Latham & Watkins advised Owkin on the deal. Covington & Burling LLP advised Sanofi. Owkin, an artificial intelligence and precision medicine...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Egle Therapeutics on the deal. Gide advised the pool of investors, while Morgan, Lewis & Bockius advised Takeda Ventures. Egle Therapeutics,...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery advised Pierre Fabre on the deal. Pierre Fabre finalized a strategic collaboration with Atara Biotherapeutics to commercialize Tab-cel® in Europe, the Middle East,...
You must be a Standard 1 Year member to access this content.
IN BRIEF: McDermott Will & Emery, advised on the matter. McDermott Will & Emery advised Pierre Fabre S.A. with a team including Anne-France Moreau (Life Science...
You must be a Standard 1 Year member to access this content.
